[Skip to Content]
[Skip to Content Landing]
Editor's Note
July 2018

Mendelian Randomization Evidence for Cardiovascular Precision Medicine

Author Affiliations
  • 1Associate Editor, JAMA Cardiology
  • 2Cardiology Section, Department of Medicine, VA Boston Healthcare System, Boston, Massachusetts
  • 3Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
JAMA Cardiol. 2018;3(7):627-628. doi:10.1001/jamacardio.2018.1543

An overarching aim of precision medicine is to direct the right treatment to the right person at the right dose at the right time. Recently, mendelian randomization (MR) studies have contributed to our evidence base for precision medicine by harnessing genetic information to assess whether associations of exposures with cardiovascular outcomes may be causal. The ascendance of MR studies takes advantage of the explosive growth of genome-wide genetic data in multiple cohorts collaborating within global meta-analyses. In MR studies, genetic variants associated with an exposure of interest serve as unconfounded proxies for altered levels of the exposure.1